Rural Communities at Risk: Global Liver Institute Champions Awareness for Rare Liver Diseases
As rural healthcare access shrinks across the United States and remains limited worldwide, Global Liver Institute (GLI) is shining a spotlight on the critical need for awareness and education about rare liver diseases during Rare Liver Diseases Month.
Global Liver Institute Supports CMS Coverage of Obesity Medications
GLI was very pleased to see the U.S. Centers for Medicare and Medicaid Services (CMS) take the step towards expanding coverage for anti-obesity medications when used to treat obesity in the Medicare Part D and Medicaid programs.
Global Liver Institute Statement on U.S. End-of-Year Health Package
GLI celebrates the release of bill text last night for a continuing resolution (CR) for FY2025 from the U.S. House of Representatives that includes Medicare coverage of multi-cancer early detection screening tests and defines standards and payments for these diagnostic tests.
The Case for Universal Access to Hepatitis C DAA Treatment for Your Patients
Hepatitis C is a viral infection of the liver caused by the hepatitis C virus (HCV) and spread through blood-to-blood exposure. The majority of people exposed to HCV develop chronic infection, which can cause cirrhosis resulting in liver failure, liver cancer, or even the need for liver transplantation.
Can Blood Tests Help Predict Liver Transplant Outcomes? – Pediatric & Rare Liver Diseases News
As we conclude this year, the Pediatric and Rare Liver Diseases team is reflecting on the incredible progress made by our council and patient organizations in 2024.